INTU vs. NBIX
INTU (Intuit Inc.) and NBIX (Neurocrine Biosciences, Inc.) are both stocks. INTU operates in Software - Application (Technology), while NBIX operates in Drug Manufacturers - Specialty & Generic (Healthcare). Over the past 10 years, INTU returned 12.10%/yr vs 12.71%/yr for NBIX. Their 0.27 correlation means their historical movements had little consistent relationship.
Performance
INTU vs. NBIX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, INTU achieves a -51.84% return, which is significantly lower than NBIX's 17.61% return. Over the past 10 years, INTU has underperformed NBIX with an annualized return of 12.10%, while NBIX has yielded a comparatively higher 12.71% annualized return.
INTU
- 1D
- 0.18%
- 1M
- 18.87%
- 6M
- -36.17%
- YTD
- -51.84%
- 1Y
- -59.29%
- 3Y*
- -13.98%
- 5Y*
- -9.16%
- 10Y*
- 12.10%
- ALL TIME*
- 16.08%
NBIX
- 1D
- -10.08%
- 1M
- -0.58%
- 6M
- 22.59%
- YTD
- 17.61%
- 1Y
- 30.08%
- 3Y*
- 17.27%
- 5Y*
- 12.34%
- 10Y*
- 12.71%
- ALL TIME*
- 9.11%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
INTU Intuit Inc. | $1.23B | $1.26B | $1.61B |
| $278.93M | $232.17M | $211.02M |
INTU vs. NBIX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
INTU Intuit Inc. | -51.84% | 6.09% | 1.16% | 61.76% | -39.12% | 70.27% | 46.12% | 34.11% | 25.86% | 39.21% |
NBIX Neurocrine Biosciences, Inc. | 17.61% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
Correlation
The correlation between INTU and NBIX is 0.08, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.08 |
Correlation (3Y) Balances recent behavior with more history. | 0.20 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.22 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.27 |
Correlation (All Time) Calculated using the full available price history since May 23, 1996 | 0.27 |
The correlation between INTU and NBIX shifts across timeframes, from 0.08 (1 year) to 0.27 (all time), reflecting how their relationship changes across market environments.
Fundamentals
INTU:
$86.46B
NBIX:
$16.77B
INTU:
$16.41
NBIX:
$6.84
INTU:
19.26
NBIX:
24.39
INTU:
1.15
NBIX:
0.48
INTU:
4.22
NBIX:
5.10
INTU:
4.23
NBIX:
4.35
INTU:
$20.93B
NBIX:
$3.37B
INTU:
$16.97B
NBIX:
$3.31B
INTU:
$6.65B
NBIX:
$940.50M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
INTU vs. NBIX — Risk / Return Rank
INTU
NBIX
INTU vs. NBIX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Intuit Inc. (INTU) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| INTU | NBIX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.17 | ||
| Sortino ratioReturn per unit of downside risk | -3.41 | ||
| Omega ratioGain probability vs. loss probability | 0.74 | 1.19 | -0.45 |
| Calmar ratioReturn relative to maximum drawdown | -0.88 | 1.45 | -2.33 |
| Martin ratioReturn relative to average drawdown | -1.49 | 3.18 | -4.67 |
Loading charts...
Drawdowns
INTU vs. NBIX - Drawdown Comparison
The maximum INTU drawdown since its inception was -75.29%, smaller than the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for INTU and NBIX.
Loading charts...
Drawdown Indicators
| INTU | NBIX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.29% | -97.21% | +21.92% |
Max Drawdown (1Y)Largest decline over 1 year | -67.28% | -20.90% | -46.38% |
Max Drawdown (3Y)Largest decline over 3 years | -68.19% | -42.89% | -25.30% |
Max Drawdown (5Y)Largest decline over 5 years | -68.19% | -42.89% | -25.30% |
Max Drawdown (10Y)Largest decline over 10 years | -68.19% | -46.39% | -21.80% |
Current DrawdownCurrent decline from peak | -60.41% | -10.08% | -50.33% |
Average DrawdownAverage peak-to-trough decline | -24.30% | -43.66% | +19.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 39.92% | 9.47% | +30.45% |
Volatility
INTU vs. NBIX - Volatility Comparison
Intuit Inc. (INTU) and Neurocrine Biosciences, Inc. (NBIX) have volatilities of 14.50% and 14.12%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| INTU | NBIX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.50% | 14.12% | +0.38% |
Volatility (6M)Calculated over the trailing 6-month period | 43.81% | 26.01% | +17.80% |
Volatility (1Y)Calculated over the trailing 1-year period | 47.33% | 33.74% | +13.59% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.29% | 33.17% | +5.12% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.35% | 39.18% | -4.83% |
Dividends
INTU vs. NBIX - Dividend Comparison
INTU's dividend yield for the trailing twelve months is around 1.52%, while NBIX has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
INTU Intuit Inc. | 1.52% | 0.65% | 0.60% | 0.52% | 0.72% | 0.38% | 0.57% | 0.74% | 0.83% | 0.89% | 1.08% | 1.09% |
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
INTU vs. NBIX - Financials Comparison
This section allows you to compare key financial metrics between Intuit Inc. and Neurocrine Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
INTU vs. NBIX - Profitability Comparison
INTU - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Intuit Inc. reported a gross profit of 7.24B and revenue of 8.56B. Therefore, the gross margin over that period was 84.6%.
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported a gross profit of 935.80M and revenue of 959.00M. Therefore, the gross margin over that period was 97.6%.
INTU - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Intuit Inc. reported an operating income of 4.02B and revenue of 8.56B, resulting in an operating margin of 47.0%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported an operating income of 151.50M and revenue of 959.00M, resulting in an operating margin of 15.8%.
INTU - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Intuit Inc. reported a net income of 3.06B and revenue of 8.56B, resulting in a net margin of 35.8%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported a net income of 144.40M and revenue of 959.00M, resulting in a net margin of 15.1%.
Frequently Asked Questions
INTU and NBIX have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
INTU has higher volatility (14.50%) compared to NBIX (14.12%). In terms of maximum drawdown, INTU dropped -75.29% vs NBIX's -97.21%.
NBIX currently has the higher Sharpe Ratio (0.91 vs -1.26), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for INTU and NBIX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer